Swetha Kommareddy, MD
Endocrinology, Diabetes & Metabolism · Worcester, MANPI 1437390119
Payments from drug & device makers
Across 14 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$182
- Abbott$88
- Tandem Diabetes Care, Inc.$82
- Medtronic$41
- Sequel Med Tech, LLC$21
- Dexcom, Inc.$18
What the payments were for
- Food & beverage$431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cequr Corporation | 3 | $182 |
| Abbott | 4 | $88 |
| Tandem Diabetes Care, Inc. | 3 | $82 |
| Medtronic | 2 | $41 |
| Sequel Med Tech, LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$110
How this compares
$431 in reported general payments places this provider in the 40th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 385 | $533,350 |
| JardianceEmpagliflozin | 239 | $257,648 |
| TrulicityDulaglutide | 169 | $238,518 |
| MounjaroTirzepatide | 170 | $210,270 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 134 | $69,556 |
| TradjentaLinagliptin | 76 | $59,043 |
| JanuviaSitagliptin Phosphate | 33 | $36,543 |
| Humalog Kwikpen U-100Insulin Lispro | 122 | $33,125 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 310 | $30,635 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $26,022 |
| Novolog FlexpenInsulin Aspart | 122 | $25,970 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $23,525 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $19,993 |
| FarxigaDapagliflozin Propanediol | 17 | $15,691 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 169 | $13,878 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Worcester
- Nina RosanoWorcester$470K
- Nitin TrivediWorcester$403K
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.